[PDF][PDF] … EFFECTIVENESS AND SAFETY OF DIRECT ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
S Suwatcharangkoon - rama.mahidol.ac.th
… 50% of sample sized taking a low dose of DOAC 4) no clear … with warfarin, dabigatran,
rivaroxaban, and apixaban were … a specific non-valvular AF with different patient characteristics …
rivaroxaban, and apixaban were … a specific non-valvular AF with different patient characteristics …
[HTML][HTML] … and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: a sub-analysis of the STANDARD study
H Inoue, M Umeyama, T Yamada, H Hashimoto… - Journal of …, 2020 - Elsevier
… to apixaban; similar findings were also reported for dabigatran and rivaroxaban [8], [18], [19],
[20], [21]. … database of NVAF patients newly initiating apixaban or warfarin showed a lower …
[20], [21]. … database of NVAF patients newly initiating apixaban or warfarin showed a lower …
Real-world oral anticoagulants for Asian patients with non-valvular atrial fibrillation: a PRISMA-compliant article
SM Kim, ET Jeon, JM Jung, JS Lee - Medicine, 2021 - journals.lww.com
… Apixaban, dabigatran, and rivaroxaban had a lower risk of SSE than warfarin. The NOACs …
In addition, only low-dose dabigatran and rivaroxaban reduced the risk of IS, in contrast to the …
In addition, only low-dose dabigatran and rivaroxaban reduced the risk of IS, in contrast to the …
Non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: evidences from the real-world data
Z Xue, Y Zhou, C Wu, J Lin, X Liu, W Zhu - Heart Failure Reviews, 2020 - Springer
… (dabigatran, rivaroxaban, apixaban, or edoxaban) versus … with warfarin, all NOACs reduced
the risks of bleeding events … 50% of patients received reduced or low dose of dabigatran, …
the risks of bleeding events … 50% of patients received reduced or low dose of dabigatran, …
… atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study
YH Chan, TF Chao, SW Chen, HF Lee… - European Heart …, 2023 - academic.oup.com
… 15 mg od, dabigatran 110 or 150 od, apixaban 2.5 mg od, or rivaroxaban 10 mg (without
the … of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal …
the … of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal …
[HTML][HTML] Real-world clinical outcomes of oral anticoagulants among Japanese patients with atrial fibrillation and concomitant coronary artery disease
Y Chen, X Gong, H Bao - IJC Heart & Vasculature, 2023 - Elsevier
… and CAD commencing warfarin, dabigatran, or rivaroxaban. … versus warfarin, while low-dose
NOACs reduced safety risks … this study did not include apixaban, prior analysis of patients …
NOACs reduced safety risks … this study did not include apixaban, prior analysis of patients …
Indirect comparison of novel oral anticoagulants among Asians with non-valvular atrial fibrillation in the real world setting: a network meta-analysis
J Zhang, J Tang, X Cui, B Wang, M Bu, Y Bai… - BMC Cardiovascular …, 2019 - Springer
… patients in this NMA received low-dose dabigatran (110 mg), … apixaban, dabigatran, and
rivaroxaban were more effective than warfarin on reducing the risks of stroke and haemorrhage; …
rivaroxaban were more effective than warfarin on reducing the risks of stroke and haemorrhage; …
[HTML][HTML] Low-dose NOACs versus standard-dose NOACs or warfarin on efficacy and safety in Asian patients with NVAF: a meta-analysis
Z Li, Y Zheng, D Li, X Wang, S Cheng… - Anatolian Journal of …, 2022 - ncbi.nlm.nih.gov
… for Asian patients with non-valvular atrial fibrillation. We aimed … Low-dose NOACs were
defined as dabigatran 110 mg bid, … together even though rivaroxaban, apixaban, and edoxaban …
defined as dabigatran 110 mg bid, … together even though rivaroxaban, apixaban, and edoxaban …
Elderly bleeding risk of direct oral anticoagulants in nonvalvular atrial fibrillation: a systematic review and meta-analysis of cohort studies
J Lobraico-Fernandez, S Baksh, E Nemec - Drugs in R&D, 2019 - Springer
… : “dabigatran OR apixaban OR rivaroxaban OR warfarin OR direct oral anticoagulant OR
DOAC” AND “non-valvular atrial fibrillation OR atrial fibrillation” … prescribed a “low-dose” DOAC. …
DOAC” AND “non-valvular atrial fibrillation OR atrial fibrillation” … prescribed a “low-dose” DOAC. …
Real-world comparisons of reduced-dose non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation: a systematic review and meta-analysis
X Wang, L Fang, B Liu, Y Zheng, J Zeng - Heart Failure Reviews, 2020 - Springer
… outcomes in low-dose NOACs (dabigatran, rivaroxaban, and … Xa inhibitors OR dabigatran
OR rivaroxaban OR apixaban OR … with decreased risks of thromboembolic and bleeding events…
OR rivaroxaban OR apixaban OR … with decreased risks of thromboembolic and bleeding events…